PCVs in individuals at increased risk of pneumococcal disease: a literature review

References

• Advisory Committee on Immunization Practices (ACIP). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61:816-19
   Google Scholar
• Active bacterial core surveillance report, emerging infections program Network, Streptococcus pneumoniae, 2010. Centers for Disease Control and Prevention. 2011. Available from: www.cdc.gov/abcs/reports-findings/survreports/spneu10.pdf [Last accessed December 2012]
   Google Scholar
• Estimated Hib and pneumococcal deaths for children under 5 years of age. World Health Organization. 2013. Available from: www.who.int/immunization/monitoring_surveillance/burden/estimates/Pneumo_hib/en/ [Last accessed December 2012]
   Google Scholar
• Myint TT, Madhava H, Balmer P, et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther 2013;30:127-51
   PubMed Web of Science ®Google Scholar
• Fitzwater SP, Chandran A, Santosham M, et al. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2012;31:501-8
   PubMed Web of Science ®Google Scholar
• Surveillance report: annual epidemiological report reporting on 2010 surveillance data and 2011 epidemic intelligence data. European Centre for Disease Prevention and Control, 2012. Available from: http://ecdc.europa.eu/en/publications/Publications/Annual-Epidemiological-Report-2012.pdf [Last accessed 13 May 2013]
   Google Scholar
• Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012;67:71-9
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012;65:17-24
   PubMed Web of Science ®Google Scholar
• Rose MA, Christopoulou D, Myint TT, et al. The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe. Int J Clin Pract 2014;68:8-19
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Averbuch D, Maury S, et al. Pneumococcal immunization in immunocompromised hosts: where do we stand? Expert Rev Vaccines 2014;13:59-74
   PubMed Web of Science ®Google Scholar
• Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013;62:521-4
   PubMed Web of Science ®Google Scholar
• Wong WY, Overturf GD, Powars DR. Infection caused by Streptococcus pneumoniae in children with sickle cell disease: epidemiology, immunologic mechanisms, prophylaxis, and vaccination. Clin Infect Dis 1992;14:1124-36
   PubMed Web of Science ®Google Scholar
• Battersby AJ, Knox-Macaulay HH, Carrol ED. Susceptibility to invasive bacterial infections in children with sickle cell disease. Pediatr Blood Cancer 2010;55:401-6
   Google Scholar
• Esposito S, Musio A, Principi N. Paediatric asthma and pneumococcal vaccination. Vaccine 2013;31:5015-19
   Google Scholar
• Pneumovax 23 summary of product characteristics. Sanofi Pasteur MSD, 2012. Available from: www.medicines.org.uk/emc/medicine/1446 [Last accessed 14 June 2013]
   Google Scholar
• Prevenar 13: summary of product characteristics. European Medicines Agency. 2015. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001104/WC500057247.pdf [Last accessed 4 June 2015]
   Google Scholar
• Prevnar 13 prescribing information. Pfizer Inc, 2012. Available from: www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201669.pdf [Last accessed 3 March 2014]
   Google Scholar
• Synoflorix summary of product characteristics. GlaxoSmithKline Biologicals S.A. 2013. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000973/WC500054346.pdf [Last accessed 4 March 2013]
   Google Scholar
• Pneumococcal vaccination (PCV) overview in European countries. EUVAC.NET, 2014. Available from: www.euvac.net/graphics/euvac/vaccination/pcv.html [Last accessed 15 January 2014]
   Google Scholar
• Castiglia P. Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe. Adv Ther 2014;31:1011-44
   PubMed Web of Science ®Google Scholar
• Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/=65 Years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014;63:822-5
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pneumococcal vaccines WHO position paper - 2012 - recommendations. Vaccine 2012;30:4717-18
   PubMed Web of Science ®Google Scholar
• Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013;1:CD000422
   PubMed Web of Science ®Google Scholar
• Wernette CM, Frasch CE, Madore D, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003;10:514-19
   PubMedGoogle Scholar
• Song JY, Moseley MA, Burton RL, et al. Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother 2013;19:412-25
   PubMed Web of Science ®Google Scholar
• WHO expert committee on biological standardization: fifty-fourth report. World Health Organization. 2005. Available from: http://whqlibdoc.who.int/trs/WHO_TRS_927_eng.pdf [Last accessed 17 October 2013]
   Google Scholar
• Romero-Steiner S, Libutti D, Pais LB, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997;4:415-22
   PubMedGoogle Scholar
• Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol 2011;164:9-16
   PubMed Web of Science ®Google Scholar
• Saari TN. Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 2003;112:193-8
   PubMed Web of Science ®Google Scholar
• Madhi SA, Kuwanda L, Cutland C, et al. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 2005;24:410-16
   PubMed Web of Science ®Google Scholar
• Papadatou I, Piperi C, Alexandraki K, et al. Antigen-Specific B-Cell Response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with beta-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis 2014;59:862-5
   PubMed Web of Science ®Google Scholar
• Orthopoulos GV, Theodoridou MC, Ladis VA, et al. The effect of 23-valent pneumococcal polysaccharide vaccine on immunological priming induced by 7-valent conjugate vaccine in asplenic subjects with beta-thalassemia. Vaccine 2009;27:350-4
   PubMed Web of Science ®Google Scholar
• Vernacchio L, Romero-Steiner S, Martinez JE, et al. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease. J Infect Dis 2000;181:1162-6
   PubMed Web of Science ®Google Scholar
• Feikin DR, Elie CM, Goetz MB, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001;20:545-53
   PubMed Web of Science ®Google Scholar
• Lesprit P, Pedrono G, Molina JM, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. Aids 2007;21:2425-34
   PubMed Web of Science ®Google Scholar
• Tobudic S, Plunger V, Sunder-Plassmann G, et al. Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients. PLoS One 2012;7:e46133
   PubMed Web of Science ®Google Scholar
• Vieira S, Baldacci ER, Carneiro-Sampaio M, et al. Evaluation of antibody response to the heptavalent pneumococcal conjugate vaccine in pediatric chronic kidney disease. Pediatr Nephrol 2009;24:83-9
   PubMed Web of Science ®Google Scholar
• Navarro D, Escribano A, Cebrian L, et al. Type-specific antibodies to pneumococcal capsular polysaccharide acquired either naturally or after vaccination with Prevenar in children with underlying chronic or recurrent lung diseases. Clin Vaccine Immunol 2006;13:665-70
   Google Scholar
• Rose MA, Gruendler M, Schubert R, et al. Safety and immunogenicity of sequential pneumococcal immunization in preschool asthmatics. Vaccine 2009;27:5259-64
   Google Scholar
• Gordon SB, Kayhty H, Molyneux ME, et al. Pneumococcal conjugate vaccine is immunogenic in lung fluid of HIV-infected and immunocompetent adults. J Allergy Clin Immunol 2007;120:208-10
   Google Scholar
• Madhi SA, Klugman KP, Kuwanda L, et al. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis 2009;199:1168-76
   PubMed Web of Science ®Google Scholar
• Nachman S, Kim S, King J, et al. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 2003;112:66-73
   PubMed Web of Science ®Google Scholar
• Meerveld-Eggink A, de Weerdt O, van Velzen-Blad H, et al. Response to conjugate pneumococcal and Haemophilus influenzae type b vaccines in asplenic patients. Vaccine 2011;29:675-80
   PubMed Web of Science ®Google Scholar
• Stanford E, Print F, Falconer M, et al. Immune response to pneumococcal conjugate vaccination in asplenic individuals. Hum Vaccin 2009;5:85-91
   PubMed Web of Science ®Google Scholar
• Nowak-Wegrzyn A, Winkelstein JA, Swift AJ, et al. Serum opsonic activity in infants with sickle-cell disease immunized with pneumococcal polysaccharide protein conjugate vaccine. The Pneumococcal Conjugate Vaccine Study Group. Clin Diagn Lab Immunol 2000;7:788-93
   Google Scholar
• O’Brien KL, Swift AJ, Winkelstein JA, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group. Pediatrics 2000;106:965-72
   PubMed Web of Science ®Google Scholar
• Reinert P, Benkerrou M, de Montalembert M, et al. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease. Pediatr Infect Dis J 2007;26:1105-9
   PubMed Web of Science ®Google Scholar
• Antin JH, Guinan EC, Avigan D, et al. Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:213-22
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Labopin M, Chesnel V, et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis 2009;48:1392-401
   PubMed Web of Science ®Google Scholar
• Meisel R, Kuypers L, Dirksen U, et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood 2007;109:2322-6
   PubMed Web of Science ®Google Scholar
• Molrine DC, Antin JH, Guinan EC, et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 2003;101:831-6
   PubMed Web of Science ®Google Scholar
• Meerveld-Eggink A, van der Velden AM, Ossenkoppele GJ, et al. Antibody response to polysaccharide conjugate vaccines after nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2009;15:1523-30
   PubMed Web of Science ®Google Scholar
• Kumar D, Chen MH, Wong G, et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis 2008;47:885-92
   Google Scholar
• Gattringer R, Winkler H, Roedler S, et al. Immunogenicity of a combined schedule of 7-valent pneumococcal conjugate vaccine followed by a 23-valent polysaccharide vaccine in adult recipients of heart or lung transplants. Transpl Infect Dis 2011;13:540-4
   PubMed Web of Science ®Google Scholar
• Lin PL, Michaels MG, Green M, et al. Safety and immunogenicity of the American Academy of Pediatrics–recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients. Pediatrics 2005;116:160-7
   PubMed Web of Science ®Google Scholar
• Sanal O, Ersoy F, Tezcan I, et al. Antibody response to a seven-valent pneumococcal conjugated vaccine in patients with ataxia-telangiectasia. J Clin Immunol 2004;24:411-17
   PubMed Web of Science ®Google Scholar
• Rose MA, Schubert R, Kujumdshiev S, et al. Immunoglobulins and immunogenicity of pneumococcal vaccination in preschool asthma. Int J Clin Pract 2006;60:1425-31
   Google Scholar
• Dransfield MT, Harnden S, Burton RL, et al. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin Infect Dis 2012;55:e35-44
   PubMed Web of Science ®Google Scholar
• Rose M, Hey C, Kujumdshiev S, et al. Immunogenicity of pneumococcal vaccination of patients with cochlear implants. J Infect Dis 2004;190:551-7
   PubMed Web of Science ®Google Scholar
• Kumar D, Rotstein C, Miyata G, et al. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003;187:1639-45
   Google Scholar
• Chen M, Ssali F, Mulungi M, et al. Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults. Vaccine 2008;26:4962-8
   PubMed Web of Science ®Google Scholar
• Deloria-Knoll M, Steinhoff M, Semba RD, et al. Effect of zinc and vitamin A supplementation on antibody responses to a pneumococcal conjugate vaccine in HIV-positive injection drug users: a randomized trial. Vaccine 2006;24:1670-9
   Google Scholar
• Slayter KL, Singer J, Lee TC, et al. Immunization against pneumococcal disease in HIV-infected patients: conjugate versus polysaccharide vaccine before or after reconstitution of the immune system (CTN-147). Int J STD AIDS 2013;24:227-31
   Google Scholar
• Sogaard OS, Lohse N, Harboe ZB, et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010;51:42-50
   PubMed Web of Science ®Google Scholar
• Sogaard OS, Schonheyder HC, Bukh AR, et al. Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. Aids 2010;24:1315-22
   PubMed Web of Science ®Google Scholar
• Miiro G, Kayhty H, Watera C, et al. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine. J Infect Dis 2005;192:1801-5
   PubMed Web of Science ®Google Scholar
• Costa Ide C, Guilardi F, Kmiliauskis MA, et al. Evaluation of humoral response to heptavalent pneumococcal conjugate vaccine in HIV-infected children. Rev Saude Publica 2008;42:844-50
   Google Scholar
• Madhi SA, Adrian P, Cotton MF, et al. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis 2010;202:355-61
   PubMed Web of Science ®Google Scholar
• Madhi SA, Izu A, Violari A, et al. Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants. Vaccine 2013;31:777-83
   PubMed Web of Science ®Google Scholar
• Spoulou VI, Tsoumas DL, Papaevangelou VG, et al. Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children. Vaccine 2005;23:5289-93
   PubMed Web of Science ®Google Scholar
• Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006;25:920-9
   PubMed Web of Science ®Google Scholar
• Abzug MJ, Song LY, Levin MJ, et al. Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy. Vaccine 2013;31:4782-90
   PubMed Web of Science ®Google Scholar
• Barton M, Wasfy S, Dipchand AI, et al. Seven-valent pneumococcal conjugate vaccine in pediatric solid organ transplant recipients: a prospective study of safety and immunogenicity. Pediatr Infect Dis J 2009;28:688-92
   PubMed Web of Science ®Google Scholar
• Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine 2010;28:5109-13
   PubMed Web of Science ®Google Scholar
• Kapetanovic MC, Roseman C, Jonsson G, et al. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Arthritis Rheum 2011;63:3723-32
   PubMedGoogle Scholar
• Kapetanovic MC, Saxne T, Jonsson G, et al. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther 2013;15:R171
   Google Scholar
• Liakou CD, Askiti V, Mitsioni A, et al. Safety, immunogenicity and kinetics of immune response to 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome. Vaccine 2011;29:6834-7
   PubMedGoogle Scholar
• Liakou CD, Askiti V, Mitsioni A, et al. Safety and immunogenicity of booster immunization with 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome. Vaccine 2014;32:1394-7
   Google Scholar
• Schubert R, Reichenbach J, Rose M, et al. Immunogenicity of the seven valent pneumococcal conjugate vaccine in patients with ataxia-telangiectasia. Pediatr Infect Dis J 2004;23:269-70
   PubMedGoogle Scholar
• Sinisalo M, Vilpo J, Itala M, et al. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine 2007;26:82-7
   PubMed Web of Science ®Google Scholar
• Cheng FW, Ip M, Chu YY, et al. Humoral response to conjugate pneumococcal vaccine in paediatric oncology patients. Arch Dis Child 2012;97:358-60
   PubMed Web of Science ®Google Scholar
• Kusters MA, Manders NC, de Jong BA, et al. Functionality of the pneumococcal antibody response in Down syndrome subjects. Vaccine 2013;31:6261-5
   Google Scholar
• Szynczewska E, Chlebna-Sokol D. Immunogenicity of heptavalent conjugate vaccine against Streptococcus pneumoniae in premature babies with low birth weight. Pediatr Neonatol 2014;55:101-7
   PubMed Web of Science ®Google Scholar
• D’Angio CT, Heyne RJ, O’Shea TM, et al. Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants. Pediatr Infect Dis J 2010;29:600-6
   PubMed Web of Science ®Google Scholar
• Shinefield H, Black S, Ray P, et al. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J 2002;21:182-6
   PubMed Web of Science ®Google Scholar
• Clutterbuck EA, Lazarus R, Yu LM, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis 2012;205:1408-16
   PubMed Web of Science ®Google Scholar
• Clutterbuck EA, Salt P, Oh S, et al. The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine. Immunology 2006;119:328-37
   PubMed Web of Science ®Google Scholar
• French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010;362:812-22
   PubMed Web of Science ®Google Scholar
• Rivera-Olivero IA, Del NB, Fuentes M, et al. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases. Vaccine 2014;32:4006-11
   PubMed Web of Science ®Google Scholar
• Uddin S, Borrow R, Haeney MR, et al. Total and serotype-specific pneumococcal antibody titres in children with normal and abnormal humoral immunity. Vaccine 2006;24:5637-44
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone NF, Huppler Hullsiek K, Roediger M, et al. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J Infect Dis 2010;202:1114-25
   PubMed Web of Science ®Google Scholar
• Shrimpton A, Duddridge M, Ziegler-Heitbrock L. Vaccination with polysaccharide-conjugate-vaccines in adult patients with specific antibody deficiency. Vaccine 2006;24:3574-80
   Google Scholar
• Cordonnier C, Labopin M, Jansen KU, et al. Relationship between IgG titers and opsonocytophagocytic activity of anti-pneumococcal antibodies after immunization with the 7-valent conjugate vaccine in allogeneic stem cell transplant. Bone Marrow Transplant 2010;45:1423-6
   Google Scholar
• Mikoluc B, Kayhty H, Bernatowska E, et al. Immune response to the 7-valent pneumococcal conjugate vaccine in 30 asplenic children. Eur J Clin Microbiol Infect Dis 2008;27:923-8
   PubMed Web of Science ®Google Scholar
• Smets F, Bourgois A, Vermylen C, et al. Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine. Vaccine 2007;25:5278-82
   PubMed Web of Science ®Google Scholar
• Stoehr GA, Rose MA, Eber SW, et al. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis. Br J Haematol 2006;132:788-90
   PubMedGoogle Scholar